Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FNTA | P49354 | 6/20 | 0.54 |
| ▸ | FNTB | P49356 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SQLE | Q14534 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17182998 | 1.00 | KMT2A (0.57) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL17182999 | 1.00 | KMT2A (0.57) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL9580063 | 0.98 | ALOX15 (0.55) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL9580059 | 0.98 | ALOX15 (0.55) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL17554314 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL5321097 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL10916255 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL10916246 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL28052471 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 | |
| SCHEMBL11215304 | 0.92 | KMT2A (0.61) | KMT2AFNTAFNTBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948245-B1 | PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES | FIRMENICH & CIE (CH) | 2018-05-30 | — | — | EP | disclosed |
| EP-2922813-B1 | HYDROCARBONYLATION OR METHOXYCARBONYLATION OF 1,3-DIENE DERIVATIVES WITH PALLADIUM COMPLEX | FIRMENICH & CIE (CH) | 2016-10-12 | — | — | EP | disclosed |
| US-9381507-B2 | Process for the preparation of 4-methylpent-3-en-1-ol derivatives | FIRMENICH SA (CH) | 2016-07-05 | — | — | US | disclosed |
| US-9376365-B2 | Hydrocarbonylation or methoxycarbonylation of 1,3-diene derivatives with palladium complex | FIRMENICH SA (CH) | 2016-06-28 | — | — | US | disclosed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20150353463-A1 | PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES | FIRMENICH SA (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150299085-A1 | HYDROCARBONYLATION OR METHOXYCARBONYLATION OF 1,3-DIENE DERIVATIVES WITH PALLADIUM COMPLEX | FIRMENICH SA (CH) | 2015-10-22 | — | — | US | disclosed |
| US-7683190-B2 | Process for the preparation of optically-active compounds | GIVAUDAN SA (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20080064886-A1 | Process for the Preparation of Optically-Active Compounds | GIVAUDAN SA (CH) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353463-A1 | PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES | CYP4A11, CYP4B1, CYP51A1 | KMT2A 391/4885FNTA 129/4885FNTB 595/4885 |
| US-20150299085-A1 | HYDROCARBONYLATION OR METHOXYCARBONYLATION OF 1,3-DIENE DERIVATIVES WITH PALLADIUM COMPLEX | PHOSPHO1, PDCD1LG2, PDK2 | KMT2A 555/4885FNTA 1235/4885FNTB 928/4885 |
| US-20080064886-A1 | Process for the Preparation of Optically-Active Compounds | ADH1C, ADH1A, CYP2E1 | KMT2A 4273/4885FNTA 228/4885FNTB 88/4885 |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | KMT2A 2693/4885FNTA 1762/4885FNTB 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.